Name of journal: World Journal of Clinical Cases

Manuscript NO: 67434

Title: High plasma CD40 ligand level is associated with more advanced stages and worse prognosis in colorectal cancer

Reviewer’s code: 00729695

Position: Peer Reviewer

Academic degree: MD, PhD

Professional title: Director

Reviewer’s Country/Territory: Japan

Author’s Country/Territory: Hungary

Manuscript submission date: 2021-04-24

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-05-13 23:07

Reviewer performed review: 2021-05-17 07:30

Review time: 3 Days and 8 Hours

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>[ ] Grade A: Excellent</th>
<th>[ ] Grade B: Very good</th>
<th>[ ] Grade C: Good</th>
<th>[Y] Grade D: Fair</th>
<th>[ ] Grade E: Do not publish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Language quality</td>
<td>[ ] Grade A: Priority publishing</td>
<td>[Y] Grade B: Minor language polishing</td>
<td>[ ] Grade C: A great deal of language polishing</td>
<td>[ ] Grade D: Rejection</td>
<td></td>
</tr>
<tr>
<td>Conclusion</td>
<td>[ ] Accept (High priority)</td>
<td>[ ] Accept (General priority)</td>
<td>[ ] Minor revision</td>
<td>[ ] Major revision</td>
<td>[Y] Rejection</td>
</tr>
<tr>
<td>Re-review</td>
<td>[ ] Yes</td>
<td>[Y] No</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Peer-reviewer statements

Peer-Review: [Y] Anonymous | [ ] Onymous

Conflicts-of-Interest: [ ] Yes | [Y] No
SPECIFIC COMMENTS TO AUTHORS

The findings in this paper is not novel, and logic and conclusion in the text seems inappropriate.
PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 67434

Title: High plasma CD40 ligand level is associated with more advanced stages and worse prognosis in colorectal cancer

Reviewer’s code: 05051844

Position: Editorial Board

Academic degree: PhD

Professional title: Academic Research, Full Professor, Research Scientist

Reviewer’s Country/Territory: Mexico

Author’s Country/Territory: Hungary

Manuscript submission date: 2021-04-24

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-05-18 16:18

Reviewer performed review: 2021-05-21 22:02

Review time: 3 Days and 5 Hours

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>[ ] Grade A: Excellent</th>
<th>[ ] Grade B: Very good</th>
<th>[ ] Grade C: Good</th>
<th>[ ] Grade D: Fair</th>
<th>[ ] Grade E: Do not publish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Language quality</td>
<td>[ ] Grade A: Priority publishing</td>
<td>[ ] Grade B: Minor language polishing</td>
<td>[ ] Grade C: A great deal of language polishing</td>
<td>[ ] Grade D: Rejection</td>
<td></td>
</tr>
<tr>
<td>Conclusion</td>
<td>[ ] Accept (High priority)</td>
<td>[ ] Accept (General priority)</td>
<td>[ ] Minor revision</td>
<td>[ ] Major revision</td>
<td>[ ] Rejection</td>
</tr>
<tr>
<td>Re-review</td>
<td>[ ] Yes</td>
<td>[ ] No</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peer-review statements</td>
<td>Peer-Review: [ ] Anonymous</td>
<td>[ ] Onymous</td>
<td>Conflicts-of-Interest: [ ] Yes</td>
<td>[ ] No</td>
<td></td>
</tr>
</tbody>
</table>
SPECIFIC COMMENTS TO AUTHORS
The strength of the study is that no previous study investigated the level of CD40L with the course of the disease. Observations In the conclusions it is mentioned; "Both the high CD40L level and the elevated platelet count were a poor prognostic sign of patient survival." In a strict sense, one can only speak of a poor prognosis for interleukin 6, the changing level of CD40L and the elevated platelet count had borderline significant values in the multivariate analysis. Do not forget that the multivariate model for survival is a more robust statistic than the univariate. Therefore, I recommend being more cautious when talking about poor prognostic factors. I recommend including table 2; the footer with the meaning of the acronym AJCC, although this is well known to readers
RE-REVIEW REPORT OF REVISED MANUSCRIPT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 67434

Title: High plasma CD40 ligand level is associated with more advanced stages and worse prognosis in colorectal cancer

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer’s code: 06176936

Position: Peer Reviewer

Academic degree: MD, PhD

Professional title: Chief Doctor, Deputy Director, Professor, Surgeon

Reviewer’s Country/Territory: Russia

Author’s Country/Territory: Hungary

Manuscript submission date: 2021-04-24

Reviewer chosen by: Yu-Lu Chen

Reviewer accepted review: 2022-02-08 09:25

Reviewer performed review: 2022-02-09 16:55

Review time: 1 Day and 7 Hours

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>[ ] Grade A: Excellent</th>
<th>[ ] Grade B: Very good</th>
<th>[ Y] Grade C: Good</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ] Grade D: Fair</td>
<td>[ ] Grade E: Do not publish</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Language quality</th>
<th>[ ] Grade A: Priority publishing</th>
<th>[ Y] Grade B: Minor language polishing</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ] Grade C: A great deal of language polishing</td>
<td>[ ] Grade D: Rejection</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Conclusion</th>
<th>[ ] Accept (High priority)</th>
<th>[ Y] Accept (General priority)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ] Minor revision</td>
<td>[ ] Major revision</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Peer-reviewer</th>
<th>Peer-Review: [ Y] Anonymous</th>
<th>[ ] Onymous</th>
</tr>
</thead>
<tbody>
<tr>
<td>statements</td>
<td>Conflicts-of-Interest: [ ] Yes [ ] No</td>
<td></td>
</tr>
</tbody>
</table>

**SPECIFIC COMMENTS TO AUTHORS**

All 22 points of the STROBE statement, which refer to the title, abstract, introduction, methods, results, and discussion sections of the article, have been fulfilled.